Being down one day brings out the best in the shorts
Perhaps it was the comment in the JPM Biotech Conference that Genzyme was finalizing the labeling details with the FDA for Kynamro. Maybe that tipped off the longs.
You know, if you look very, very, very, very hard at ARNA and how they were viewed here, in the US, versus by the EMA, you might come to realize that it's not a fair world and that many markets are still closed to US companies. That's my opinion. What was the "safest drug to come along in 40 years" is suddenly under the 140 question knife with the EMA and analysts are doubtful for ARNA in the EU, getting a license...ever. ARNA was directly attacked, that through one view of their data, it looked like 3 % efficacy. In contrast, ISIS 37% efficacy was not challenged by the EMA. Is that not an interesting point????? particularly for the class actions now roiling?
I don't know quite how to take it, but I do know, through all appearance, the FDA is trying to get the label right and let the drs and their patients decide. The EMA looks to be keeping their markets closed to Yankees. Plain and simple.
Kynamro being effective, whatever the label may be, and effective by way of hitting new targets the existing drugs do not hit, seems to me the FDA has to approve this antisense drug.
it also seems very obvious, the moment on antisense drug breaks through, depending upon the patent estate, perhaps hundreds can follow... ISIS seems to have its act together and seems to have been rowing in the proper direction. You cannot fault their partnerships and cash flow from same.